GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » FCF Yield %

JSPR (Jasper Therapeutics) FCF Yield % : -86.86 (As of Mar. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Jasper Therapeutics's Trailing 12-Month Free Cash Flow is $-63.15 Mil, and Market Cap is $72.71 Mil. Therefore, Jasper Therapeutics's FCF Yield % for today is -86.86%.

The historical rank and industry rank for Jasper Therapeutics's FCF Yield % or its related term are showing as below:

JSPR' s FCF Yield % Range Over the Past 10 Years
Min: -108.34   Med: 0   Max: 0
Current: -86.86


JSPR's FCF Yield % is ranked worse than
82.2% of 1500 companies
in the Biotechnology industry
Industry Median: -14.58 vs JSPR: -86.86

Jasper Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.


Jasper Therapeutics FCF Yield % Historical Data

The historical data trend for Jasper Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics FCF Yield % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
FCF Yield %
- -12.15 -252.71 -59.41 -19.66

Jasper Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -75.88 -14.23 -13.81 -20.31 -26.44

Competitive Comparison of Jasper Therapeutics's FCF Yield %

For the Biotechnology subindustry, Jasper Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jasper Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's FCF Yield % falls into.


;
;

Jasper Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Jasper Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-63.154 / 321.17036
=-19.66%

Jasper Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-21.23 * 4 / 321.17036
=-26.44%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jasper Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Jasper Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jasper Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Executives
Jeetinder Singh Mahal officer: Chief Operating Officer C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Velan Capital Master Fund Lp other: See Footnote 1 1055B POWERS PLACE, ALPHARETTA GA 30009
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Thomas G Wiggans director
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ron Martell director, officer: President, CEO & Director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French director C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster director, 10 percent owner 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Qiming U.s. Healthcare Fund Ii, L.p. 10 percent owner 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade 10 percent owner C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004